We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects.
- Authors
Mannucci, Edoardo; Ognibene, Agostino; Cremasco, Francesco; Bardini, Gianluca; Mencucci, Antonella; Pierazzuoli, Enrica; Ciani, Silvia; Messeri, Gianni; Rotella, Carlo M.; Mannucci, E; Ognibene, A; Cremasco, F; Bardini, G; Mencucci, A; Pierazzuoli, E; Ciani, S; Messeri, G; Rotella, C M
- Abstract
<bold>Objective: </bold>To evaluate the effects of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels.<bold>Research Design and Methods: </bold>A total of 10 obese nondiabetic male patients were studied before and after a 14-day treatment with 2,550 mg/day metformin and were compared with 10 untreated obese control subjects. On days 0 and 15, leptin and GLP-1(7-36)amide/(7-37) levels were assessed before and after an oral glucose load during a euglycemic hyperinsulinemic clamp to avoid the interference of variations of insulinemia and glycemia on GLP-1 and leptin secretion. The effects of metformin on GLP-1(7-36)amide degradation in human plasma and in a buffer solution containing dipeptidyl peptidase IV (DPP-IV) were also studied.<bold>Results: </bold>Leptin levels were not affected by the oral glucose load, and they were not modified after metformin treatment. Metformin induced a significant (P < 0.05) increase of GLP-1(7-36)amide/(7-37) at 30 and 60 min after the oral glucose load (63.8 +/- 29.0 vs. 50.3 +/- 15.6 pmol/l and 75.8 +/- 35.4 vs. 46.9 +/- 20.0 pmol/l, respectively), without affecting baseline GLP-1 levels. No variations of GLP-1 levels were observed in the control group. In pooled human plasma, metformin (0.1-0.5 microg/ml) significantly inhibited degradation of GLP-1(7-36)amide after a 30-min incubation at 37 degrees C; similar results were obtained in a buffer solution containing DPP-IV.<bold>Conclusions: </bold>Metformin significantly increases GLP-1 levels after an oral glucose load in obese nondiabetic subjects; this effect could be due to an inhibition of GLP-1 degradation.
- Subjects
HYPERGLYCEMIA treatment; OVERWEIGHT persons; GLUCAGON-like peptide 1; LEPTIN; HYPOGLYCEMIC agents; METFORMIN; BLOOD sugar; CLINICAL trials; COMPARATIVE studies; GLUCAGON; RESEARCH methodology; MEDICAL cooperation; OBESITY; PEPTIDES; RESEARCH; EVALUATION research; RANDOMIZED controlled trials; GLUCAGON-like peptides; GLUCOSE clamp technique
- Publication
Diabetes Care, 2001, Vol 24, Issue 3, p489
- ISSN
0149-5992
- Publication type
journal article
- DOI
10.2337/diacare.24.3.489